IBDEI1IC ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,24109,1,4,0)
 ;;=4^L03.021
 ;;^UTILITY(U,$J,358.3,24109,2)
 ;;=^5009022
 ;;^UTILITY(U,$J,358.3,24110,0)
 ;;=L03.022^^107^1201^19
 ;;^UTILITY(U,$J,358.3,24110,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24110,1,3,0)
 ;;=3^Acute Lymphangitis of Left Finger
 ;;^UTILITY(U,$J,358.3,24110,1,4,0)
 ;;=4^L03.022
 ;;^UTILITY(U,$J,358.3,24110,2)
 ;;=^5009023
 ;;^UTILITY(U,$J,358.3,24111,0)
 ;;=L03.031^^107^1201^113
 ;;^UTILITY(U,$J,358.3,24111,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24111,1,3,0)
 ;;=3^Cellulitis of Right Toe
 ;;^UTILITY(U,$J,358.3,24111,1,4,0)
 ;;=4^L03.031
 ;;^UTILITY(U,$J,358.3,24111,2)
 ;;=^5009025
 ;;^UTILITY(U,$J,358.3,24112,0)
 ;;=L03.032^^107^1201^106
 ;;^UTILITY(U,$J,358.3,24112,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24112,1,3,0)
 ;;=3^Cellulitis of Left Toe
 ;;^UTILITY(U,$J,358.3,24112,1,4,0)
 ;;=4^L03.032
 ;;^UTILITY(U,$J,358.3,24112,2)
 ;;=^5009026
 ;;^UTILITY(U,$J,358.3,24113,0)
 ;;=L03.041^^107^1201^27
 ;;^UTILITY(U,$J,358.3,24113,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24113,1,3,0)
 ;;=3^Acute Lymphangitis of Right Toe
 ;;^UTILITY(U,$J,358.3,24113,1,4,0)
 ;;=4^L03.041
 ;;^UTILITY(U,$J,358.3,24113,2)
 ;;=^5009028
 ;;^UTILITY(U,$J,358.3,24114,0)
 ;;=L03.042^^107^1201^21
 ;;^UTILITY(U,$J,358.3,24114,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24114,1,3,0)
 ;;=3^Acute Lymphangitis of Left Toe
 ;;^UTILITY(U,$J,358.3,24114,1,4,0)
 ;;=4^L03.042
 ;;^UTILITY(U,$J,358.3,24114,2)
 ;;=^5009029
 ;;^UTILITY(U,$J,358.3,24115,0)
 ;;=M34.0^^107^1201^289
 ;;^UTILITY(U,$J,358.3,24115,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24115,1,3,0)
 ;;=3^Progressive Systemic Sclerosis
 ;;^UTILITY(U,$J,358.3,24115,1,4,0)
 ;;=4^M34.0
 ;;^UTILITY(U,$J,358.3,24115,2)
 ;;=^5011778
 ;;^UTILITY(U,$J,358.3,24116,0)
 ;;=M34.1^^107^1201^92
 ;;^UTILITY(U,$J,358.3,24116,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24116,1,3,0)
 ;;=3^CR(E)ST Syndrome
 ;;^UTILITY(U,$J,358.3,24116,1,4,0)
 ;;=4^M34.1
 ;;^UTILITY(U,$J,358.3,24116,2)
 ;;=^5011779
 ;;^UTILITY(U,$J,358.3,24117,0)
 ;;=M34.2^^107^1201^313
 ;;^UTILITY(U,$J,358.3,24117,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24117,1,3,0)
 ;;=3^Systemic Sclerosis Induced by Drug/Chemical
 ;;^UTILITY(U,$J,358.3,24117,1,4,0)
 ;;=4^M34.2
 ;;^UTILITY(U,$J,358.3,24117,2)
 ;;=^5011780
 ;;^UTILITY(U,$J,358.3,24118,0)
 ;;=M34.81^^107^1201^315
 ;;^UTILITY(U,$J,358.3,24118,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24118,1,3,0)
 ;;=3^Systemic Sclerosis w/ Lung Involvement
 ;;^UTILITY(U,$J,358.3,24118,1,4,0)
 ;;=4^M34.81
 ;;^UTILITY(U,$J,358.3,24118,2)
 ;;=^5011781
 ;;^UTILITY(U,$J,358.3,24119,0)
 ;;=M34.82^^107^1201^316
 ;;^UTILITY(U,$J,358.3,24119,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24119,1,3,0)
 ;;=3^Systemic Sclerosis w/ Myopathy
 ;;^UTILITY(U,$J,358.3,24119,1,4,0)
 ;;=4^M34.82
 ;;^UTILITY(U,$J,358.3,24119,2)
 ;;=^5011782
 ;;^UTILITY(U,$J,358.3,24120,0)
 ;;=M34.83^^107^1201^317
 ;;^UTILITY(U,$J,358.3,24120,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24120,1,3,0)
 ;;=3^Systemic Sclerosis w/ Polyneuropathy
 ;;^UTILITY(U,$J,358.3,24120,1,4,0)
 ;;=4^M34.83
 ;;^UTILITY(U,$J,358.3,24120,2)
 ;;=^5011783
 ;;^UTILITY(U,$J,358.3,24121,0)
 ;;=M34.89^^107^1201^314
 ;;^UTILITY(U,$J,358.3,24121,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24121,1,3,0)
 ;;=3^Systemic Sclerosis NEC
 ;;^UTILITY(U,$J,358.3,24121,1,4,0)
 ;;=4^M34.89
 ;;^UTILITY(U,$J,358.3,24121,2)
 ;;=^5011784
